Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort - PubMed
4 hours ago
- #real-world evidence
- #multiple sclerosis
- #treatment efficacy
- Ofatumumab significantly reduced annualized relapse rate by 94.5%, from 0.486 to 0.027 (p < 0.001), across all patient subgroups including treatment-naïve and switchers.
- At 12 months, 79.3% of evaluable patients achieved NEDA-3 (no evidence of disease activity), with similar rates among treatment-naïve, MET, and HET switchers.
- Infections were significantly higher in HET switchers (9.5%) compared to MET switchers (1.7%) and naïve patients (0.9%) (p = 0.001), with prior HET exposure as an independent predictor.
- Ofatumumab was generally well-tolerated with low discontinuation rates, mainly mild injection-related reactions, and discontinuations often due to pregnancy planning with favorable outcomes.
- The study supports ofatumumab as an effective and safe option for RMS, recommending enhanced infection monitoring in patients switching from high-efficacy therapies.